Skip to main content

Advertisement

SpringerLink
Log in

Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

The treatment of ovarian tumors is carried out with platinum medicine which can lead to incompatibilities or resistances. Thus, it is of great interest to check new medicine suitability for its application. AZD1152 is an Aurora kinase inhibitor predominantly works against Aurora kinase B involved in the chromosome segregation. Cells become polyploidy and reduce the proliferation by this impairment. To investigate whether AZD1152, may play a role in the treatment of ovarian carcinoma we serving it to the cisplatinum-resistant cell line SKOV3 alone and in combination with platinum.

Methods

We look at the proliferation, the ploidy, the phases of cell cycle and the apoptosis activity of the cells.

Results and conclusion

We could show that the combination of both medicines in the preclinical experiment produces a working advantage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res Off J Am Assoc Cancer Res 14(6):1639–1648

    Article  CAS  Google Scholar 

  2. Tang C-JC, Lin C-Y, Tang TK (2006) Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 290(2):398–410

    Article  PubMed  CAS  Google Scholar 

  3. Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, Wang PH, Yuan CC (2009) Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 455(5):431–440. doi:10.1007/s00428-009-0838-3

    Article  PubMed  CAS  Google Scholar 

  4. Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A (2009) Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 89(12):1364–1373

    Article  PubMed  CAS  Google Scholar 

  5. Pohl A, Azuma M, Zhang W, Yang D, Ning Y, Winder T, Danenberg K, Lenz HJ (2011) Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J 11(2):93–99

    Article  PubMed  CAS  Google Scholar 

  6. Esposito F, Libertini S, Franco R, Abagnale A, Marra L, Portella G, Chieffi P (2009) Aurora B expression in post-puberal testicular germ cell tumours. J Cell Physiol 221(2):435–439

    Article  PubMed  CAS  Google Scholar 

  7. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S (2010) The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52(1):63–71. doi:10.1016/j.jhep.2009.10.013

    Article  PubMed  CAS  Google Scholar 

  8. Kwon YJ, Lee SJ, Koh JS, Kim SH, Kim YJ, Park JH (2009) Expression patterns of aurora kinase B, heat shock protein 47, and periostin in esophageal squamous cell carcinoma. Oncol Res 18(4):141–151

    Article  PubMed  CAS  Google Scholar 

  9. Shen YC, Hu FC, Jeng YM, Chang YT, Lin ZZ, Chang MC, Hsu C, Cheng AL (2009) Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res 18(2):417–423. doi:10.1158/1055-9965.EPI-08-0691

    Google Scholar 

  10. Tanaka S, Arii S (2010) Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma. J Hepato-Biliary-Pancreatic Sci 17(4):413–419. doi:10.1007/s00534-009-0238-8

    Article  Google Scholar 

  11. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res Off J Am Assoc Cancer Res 13(12):3682–3688. doi:10.1158/1078-0432.CCR-06-2979

    Article  CAS  Google Scholar 

  12. Kaestner P, Stolz A, Bastians H (2009) Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 8(7):2046–2056. doi:10.1158/1535-7163.MCT-09-0323

    Article  PubMed  CAS  Google Scholar 

  13. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS (2006) Validating Aurora B as an anti-cancer drug target. J Cell Sci 119(Pt 17):3664–3675. doi:10.1242/jcs.03145

    Article  PubMed  CAS  Google Scholar 

  14. Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, Ye X (2005) Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett 579(16):3385–3391. doi:10.1016/j.febslet.2005.04.080

    Article  PubMed  CAS  Google Scholar 

  15. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC, Lee MH (2010) Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol cancer 9:42. doi:10.1186/1476-4598-9-42

    Article  PubMed  Google Scholar 

  16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA: Cancer J Clin 59(4):225–249. doi:10.3322/caac.20006

  17. Armstrong DK (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(Suppl 5):20–28

    Article  PubMed  CAS  Google Scholar 

  18. Markman M (2008) Pharmaceutical management of ovarian cancer : current status. Drugs 68(6):771–789

    Article  PubMed  CAS  Google Scholar 

  19. Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A, Hoch U, Hogan JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman JA, Stockett DE, Teague JN, Zimmerman KM, Taverna P (2010) SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol 65(4):707–717. doi:10.1007/s00280-009-1076-8

    Article  PubMed  CAS  Google Scholar 

  20. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK (2008) Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res Off J Am Assoc Cancer Res 14(17):5437–5446. doi:10.1158/1078-0432.CCR-07-4922

    Article  CAS  Google Scholar 

  21. Fogh J (1975) Human tumor cells in vitro. Plenum Press, New York

  22. The R Project for Statistical Computing. http://www.r-project.org/

  23. Nair JS, de Stanchina E, Schwartz GK (2009) The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res Off J Am Assoc Cancer Res 15(6):2022–2030. doi:10.1158/1078-0432.CCR-08-1826

    Article  CAS  Google Scholar 

  24. Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS (2008) Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 6:79. doi:10.1186/1479-5876-6-79

    Article  PubMed  Google Scholar 

  25. Li J, Anderson MG, Tucker LA, Shen Y, Glaser KB, Shah OJ (2009) Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. Cell Death Differ 16(3):498–511. doi:10.1038/cdd.2008.174

    Article  PubMed  CAS  Google Scholar 

  26. Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM (2006) Mismatch repair and treatment resistance in ovarian cancer. BMC cancer 6:201. doi:10.1186/1471-2407-6-201

    Article  PubMed  Google Scholar 

  27. Marumoto T, Zhang D, Saya H (2005) Aurora-A—a guardian of poles. Nat Rev Cancer 5(1):42–50. doi:10.1038/nrc1526

    Article  PubMed  CAS  Google Scholar 

  28. Gully CP, Velazquez-Torres G, Shin JH, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, Guma S, Phan L, Chou PC, Su CH, Zhang F, Chen JS, Yang TY, Yeung SC, Lee MH (2012) Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci USA 109(24):E1513–E1522. doi:10.1073/pnas.1110287109

    Article  PubMed  CAS  Google Scholar 

  29. Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52(15):4196–4199

    PubMed  CAS  Google Scholar 

  30. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K, Saya H (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114(5):585–598

    Article  PubMed  CAS  Google Scholar 

  31. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW, Ouchi T (2004) BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 279(19):19643–19648. doi:10.1074/jbc.M311780200

    Article  PubMed  CAS  Google Scholar 

  32. Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S, Schellens JH (2011) Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol Off J Eur Soc Med Oncol/ESMO 22(2):431–437. doi:10.1093/annonc/mdq344

    Google Scholar 

Download references

Acknowledgments

These studies became financed by annual remedies for research of the state Schleswig–Holstein, assigned to by the Christian-Albrechts-University in Kiel. The Aurora-Kinase inhibitor active drug AZD1152-HQPA was provided to us by the company AstraZeneca UK Ltd., Alderley Park, Cheshire, UK. There is no financial dependence. All primary data are accessible to the authors. A special thanks to Dr. Nicole von Wurmb-Schwark PhD and her colleagues from the Institute of Legal Medicine, University of Kiel for STR fingerprint analysis. For the diction and editing in her mother tongue we are very gratefully to Mrs. Mary Walter.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, People’s Republic of China

    Yaxi Ma

  2. Department of Gynaecology and Obstetrics, UKSH Campus Kiel, Arnold-Heller-Str. 3, House 24, 24105, Kiel, Germany

    Jörg Weimer, Regina Fredrik, Felix Hilpert, Christel Eckmann-Scholz, Norbert Arnold & Christian Schem

  3. Department of Immunology, UKSH Campus Kiel, Kiel, Germany

    Sabine Adam-Klages

  4. Institute for Experimental Medicine c/o Clinic for Internal Medicine I, UKSH-Campus Kiel, Kiel, Germany

    Susanne Sebens

  5. Institute of Medical Informatics and Statistics, Christian Albrechts University and the University Hospital Schleswig-Holstein, Kiel, Germany

    Amke Caliebe

Authors
  1. Yaxi Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg Weimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Regina Fredrik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabine Adam-Klages
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susanne Sebens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amke Caliebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Felix Hilpert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christel Eckmann-Scholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Norbert Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Christian Schem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörg Weimer.

Additional information

Y. Ma and J. Weimer contributed equally to this article.

N. Arnold and C. Schem shared senior authorship.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, Y., Weimer, J., Fredrik, R. et al. Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3. Arch Gynecol Obstet 288, 173–182 (2013). https://doi.org/10.1007/s00404-013-2719-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-2719-x

Keywords

Search

Navigation